middle.news
Can Cleo Diagnostics Turn Rising Losses Into FDA Approval for Ovarian Cancer Test?
7:04pm on Wednesday 25th of February, 2026 AEDT
•
Healthcare
Read Story
Can Cleo Diagnostics Turn Rising Losses Into FDA Approval for Ovarian Cancer Test?
7:04pm on Wednesday 25th of February, 2026 AEDT
Key Points
Revenues down 53.3% to $89,119 for half-year ended December 2025
Net loss after tax increased slightly to $1.98 million
FDA pivotal clinical trial ongoing with 18 active sites and 500-patient recruitment target
Raised $5 million via placement, cash balance at $9.4 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CLEO DIAGNOSTICS (ASX:COV)
OPEN ARTICLE